SNX-5422

DB06070InvestigationalSmall molecule

SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across...

Mechanism: SNX-5422 is a direct, potent inhibitor of Hsp90 across a broad range of human cancer cell lines and causes degradation of important Hsp90 client proteins including HER2, AKT and ERK.
Curator reviewed
Primary indication: Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
Formula / weight: C₂₅H₃₀F₃N₅O₄ · 521.541 g/mol (avg)
Code names: PF-04929113 · PF-4929113 · SNX-5422

Resolves to

Compound

UNIIBF52J69Q8TCAS908115-27-5ChEMBLCHEMBL1195136PubChem44195571

Structure

InChIKeyAVDSOVJPJZVBTC-CTYIDZIISA-NSMILESCC1(C)CC2=C(C(=NN2C2=CC(N[C@H]3CC[C@@H](CC3)OC(=O)CN)=C(C=C2)C(N)=O)C(F)(F)F)C(=O)C1

Targets

P08238HSP90AB1P07900HSP90AA1

What you can answer from here — as of January 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with SNX-5422, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account